UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2222-5
Program Prior Authorization/Medical Necessity
Medications Enspryng™ (satralizumab-mwge)
P&T Approval Date 10/2020, 10/2021, 10/2022, 10/2023, 10/2024
Effective Date 1/1/2025
1. Background:
Enspryng (satralizumab-mwge) is an interleukin-6 (IL-6) receptor antagonist indicated for the
treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-
aquaporin-4 (AQP4) antibody positive.
2. Coverage Criteriaa:
A. Initial Authorization
1. Enspryng will be approved based on all of the following criteria:
a. Diagnosis of neuromyelitis optica spectrum disorder (NMOSD)
-AND-
b. Patient has a positive serologic test for anti-aquaporin-4 (AQP4) antibodies
-AND-
c. History of failure, contraindication, or intolerance to rituximab therapy
-AND-
d. One of the following:
(1) History of one or more relapses that required rescue therapy during the previous 12
months
-OR-
(2) History of two or more relapses that required rescue therapy during the previous 24
months
-AND-
e. Prescribed by, or in consultation with, a neurologist
-AND-
© 2024 UnitedHealthcare Services, Inc.
1
f. Patient is not receiving Enspryng in combination with any of the following:
(1) Disease modifying therapies for the treatment of multiple sclerosis [e.g., Gilenya
(fingolimod), Tecfidera (dimethyl fumarate), Ocrevus (ocrelizumab), etc.]
(2) Complement inhibitors [e.g., Soliris (eculizumab), Ultomiris (ravulizumab), etc.]
(3) Anti-IL6 therapy [e.g., Actemra (tocilizumab)]
(4) B-cell depletion therapy [e.g., rituximab, Uplizna (inebilizumb-cdon)]
Authorization will be issued for 12 months.
B. Reauthorization
1. Enspryng will be approved based on all of the following criteria:
a. Documentation of positive clinical response to Enspryng therapy
-AND-
b. Prescribed by, or in consultation with, a neurologist
-AND-
c. Patient is not receiving Enspryng in combination with any of the following:
(1) Disease modifying therapies for the treatment of multiple sclerosis [e.g., Gilenya
(fingolimod), Tecfidera (dimethyl fumarate), Ocrevus (ocrelizumab), etc.]
(2) Complement inhibitors [e.g., Soliris (eculizumab), Ultomiris (ravulizumab), etc.]
(3) Anti-IL6 therapy [e.g., Actemra (tocilizumab)]
(4) B-cell depletion therapy [e.g., rituximab, Uplizna (inebilizumb-cdon)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan
coverage may also impact coverage criteria. Other policies and utilization management programs may
apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Enspryng [package insert]. South San Francisco, CA: Genentech, Inc.; March 2022.
2. Sellner J1, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of
neuromyelitis optica. Eur J Neurol. 2010 Aug;17(8):1019-32.
3. Sato D, Callegaro D, Lana-Peixoto MA, Fujihara K. Treatment of neuromyelitis optica: an
evidencebased review. Arq Neuropsiquiatr 2012;70(1);59-66.
© 2024 UnitedHealthcare Services, Inc.
2
4. Ciron J, Audoin B, Bourre B, et al. Recommendations for the use of rituximab in neuromyelitis
optica spectrum disorders. Rev Neurol (Paris). 2018 Apr;174(4):255-264.
5. Nikoo Z, Badihian S, Shaygannejad V, et al. Comparison of the efficacy of azathioprine and
rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017
Sep;264(9):2003-2009.
6. Gao F, Chai B, Gu C, et al. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis.
BMC Neurol. 2019 Mar 6;19(1):36.
7. Kim SH, Huh SY, Lee SJ, et al. A 5-year follow-up of rituximab treatment in patients with
neuromyelitis optica spectrum disorder. JAMA Neurol. 2013 Sep 1;70(9):1110-7.
8. Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum
disorder. N Engl J Med. 2019;381(22):2114-2124.
9. Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy
in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-
controlled phase 3 trial. Lancet Neurol. 2020;19(5):402-412.
Program Prior Authorization/Medical Necessity – Enspryng (satralizumab-
mwge)
Change Control
10/2020 New program.
10/2021 Annual review with no changes to clinical criteria.
10/2022 Annual review with no changes to clinical criteria. Updated reference.
10/2023 Annual review with no changes.
10/2024 Annual review with no changes to clinical criteria. Updated examples of
complement inhibitors.
© 2024 UnitedHealthcare Services, Inc.
3